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ABSTRACT:
Germline mutations in CDKN2A and/or red hair color variants in MC1R genes are 
associated with an increased susceptibility to develop cutaneous melanoma or non 
melanoma skin cancer. 
We studied the impact of the CDKN2A germinal mutation p.G101W and MC1R 
variants on gene expression and transcription profiles associated with skin cancer. 
To this end we set-up primary skin cell co-cultures from siblings of melanoma prone-
families that were later analyzed using the expression array approach.
As a result, we found that 1535 transcripts were deregulated in CDKN2A mutated 
cells, with over-expression of immunity-related genes (HLA-DPB1, CLEC2B, IFI44, 
IFI44L, IFI27, IFIT1, IFIT2, SP110 and IFNK) and down-regulation of genes playing 
a role in the Notch signaling pathway. 3570 transcripts were deregulated in MC1R 
variant carriers. In particular, genes related to oxidative stress and DNA damage 
pathways were up-regulated as well as genes associated with neurodegenerative 
diseases such as Parkinson’s, Alzheimer and Huntington. 
Finally, we observed that the expression signatures indentified in phenotypically 
normal cells carrying CDKN2A mutations or MC1R variants are maintained in skin 
cancer tumors (melanoma and squamous cell carcinoma). These results indicate 
that transcriptome deregulation represents an early event critical for skin cancer 
development.
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INTRODUCTION
The worldwide incidence of skin cancer, including 
non melanoma skin cancer (NMSC) and cutaneous 
melanoma (CM), is rapidly increasing, being the most 
common human cancer[1]. While, both entities are 
influenced by the carcinogenic effect of UV exposure, their 
incidence and tumor aggressiveness differ considerably, 
CM being the least frequent and most aggressive form[2] .
Approximately, 10% of total melanoma cases 
originate in individuals belonging to high-risk melanoma 
pedigrees. To date, CDKN2A is the major gene associated 
with the high risk inherited in melanoma prone families 
[3] and in multiple primary melanoma patients [4]. 
CDKN2A acts as a tumor suppressor gene, negatively 
regulating cell cycle progression and promoting cellular 
senescence. Recently, a role for CDKN2A in cellular 
oxidative stress regulation has been suggested [5, 6]. 
Recurrent CDKN2A mutations have been identified in 
melanoma families [7-11], mutation p.G101W being the 
most frequent one detected in Mediterranean pedigrees 
[12]. Although heterozygous loss of CDKN2A is sufficient 
to confer a 67% lifetime risk of melanoma [13], the 
mechanisms responsible for tumor enhancement still have 
to be clarified [14]. In contrast, the role of high-penetrance 
CDKN2A mutations in NMSC susceptibility has not been 
clearly elucidated [15, 16].
Skin cancer epidemiology is complex due to 
the multigenic nature of the disease. In particular, the 
MC1R gene is a key regulator of skin pigmentation and 
melanocyte differentiation, playing a central role in 
determining the pigmentation phenotype, sun sensitivity 
and tanning ability[17]. Certain MC1R polymorphisms 
are responsible for the red hair color (RHC) phenotype 
(red hair, fair skin and poor tanning response)[18] which 
is associated with high UV-radiation sensitivity and 
skin cancer susceptibility (CM and NMSC)[19, 20]. 
Furthermore, MC1R variants are a modifying factor for 
melanoma risk in CDKN2A mutation carriers, [21-23] 
suggesting that multiple medium- and low-penetrance 
genes may influence the risk conferred by high penetrance 
melanoma genes.
To date, there is a lack of information about the 
mechanisms underlying the increased skin cancer risk in 
carriers of CDKN2A mutations in association with MC1R 
variants. The effect of both genes has been separately 
investigated using murine-derived melanocytes and/
or focused on mono-cultured melanocytes [6, 24-26]. 
However, these mono-cultures exhibit phenotypic 
characteristics closely mimicking those observed in 
transformed melanocytes, such as elevated growth rate 
[27, 28] and acquired expression of melanoma-associated 
antigens[29, 30] which are abolished when they are co-
cultured with keratinocytes[30-32]. This data indicates 
that melanocyte proliferation and behavior is controlled by 
surrounding basal keratinocytes which regulate epidermal 
homeostasis [33, 34]. Thus, the establishment and 
characterization of a melanocyte–keratinocyte co-culture 
system is essential for elucidating the early molecular 
events leading to skin cancer.
The aim of the present study was to investigate the 
global molecular effect of germinal CDKN2A mutations 
(p.G101W) and MC1R RHC variants in the transcriptome 
of primary skin cells from individuals belonging to skin 
cancer prone families (familial melanoma pedigrees). 
RESULTS
Impact of CDKN2A germinal mutation p.G101W 
on Global Transcript Profiles of skin primary 
cultures: 
Whole genome expression profiling was performed 
on melanoctye-keratinocyte co-cultures from CDKN2A 
mutation carriers (samples A1 and B1 described in Table 
1) and wild-type CDKN2A individuals (samples A2 and 
B2). After stringent microarray data filtering, 1536 of 
the initial 19596 transcripts on the array were found to 
be differentially expressed in CDKN2A mutated cultured 
cells. Specifically, 60.7% of transcripts were found to 
be up-regulated (933/1536) and 39.3% of them down-
regulated (603/1536). 
Class comparison generated a signature of 108 
unique genes that significantly discriminated between 
CDKN2A mutation and non-mutation (p-value <0.0001, 
listed in Table S1). Functional categorization of those 
transcripts belonging to known genes (Figure 1a, Figure 
1b) showed that the mutant CDKN2A signature included 
deregulation of a vast number of genes involved in cell 
component and metabolism (37% up-regulated and 42% 
down-regulated,). Notably, immunomodulation and 
interferon response genes represented the second most 
prevalent subset of up-regulated transcripts (24%) and 
third down-regulated subgroup (13%) which may reflect 
a constitutively altered cytokine and chemokine profile 
in mutant cells. The set of deregulated genes involved 
in immunomodulation and interferon response includes: 
CLEC2B, IFI44L, IFIT1, IFI44, IFI27, IFNK, DDX58, 
RNF182, IFIT2, IL15, SP110, BTN3A2, RFX2, IL17D and 
HLA-DPB1 (Figure 2). The molecular profile also included 
deregulation of genes which may confer a phenotype with 
the capability for malignant transformation since they are 
involved in cell adhesion, cell growth and proliferation. 
Over-expression of apoptosis related genes CASP3, XAF1 
and SAMD9 was also detected. Transcription factors such 
as CEBPZ, LEF1, MACC1, TBX1, ZNF404 and ZNF8, 
epidermal differentiation and melanogenesis genes such 
as KRT2, TYPR1, LIMS3, EEA1 and MFI2 were also 
components of the mutant CDKN2A signature. 
Further examination by functional enrichment 
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analysis revealed an over-representation of down-
regulated genes from the Notch signaling pathway 
(hsa_04330; p=0.038) in mutant CDKN2A skin cells 
including NCOR2, PSEN, DLLC1, DVL3, NOTCH3, 
Figure 1: Impact of germinal CDKN2A mutation on global transcript profile in melanocyte-keratinocyte co-culture 
system. Functional classification of the set of 78 of 108 deregulated genes in CDKN2A mutants are indicated in Fig.1a Up-regulated 
genes and Fig.1b Down-regulated genes. T. Factors (transcription factors), Immune modulation & IFN (Immunomodulation and interferon 
related genes); Cell. Components and metabolism (Cellular components and metabolism), Diff & Melanogenesis (differentiation and 
melanogenesis)
Table 1: Genotype and phenotype features of four individuals from 
two melanoma pedigrees.
Pedigree A 
Individual MM* CDKN2A MC1R Skin phototype Eye color Hair color
A1 5 p.G101W p.R160W, 
p.R151C
II Green Red
A2 0 Wild-type p.R160W, 
p.R151C
II Green Red
Pedigree B
Individual MM* CDKN2A MC1R Skin phototype Eye color Hair color
B1 0 p.G101W Wild-type II Blue Black
B2 0 Wild-type Wild-type II Blue Brown
Two siblings from each pedigree (A and B) were included. Each individual was considered as a “genomic 
condition” in the study. A total of two and three melanoma cases have been found in pedigree A and 
B, respectively. Abbreviations: CDKN2A: cyclin-dependent kinase inhibitor 2A; MC1R: melanocortin 1 
receptor; MM: melanomas. * Number of melanomas in each individual.
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RFNG and the co-activator MAML1 which controls the 
growth-promoting effect of Notch1. 
Impact of non-functional MC1R gene on Global 
Transcript Profiles of skin primary cultures:
MC1R analysis was carried out following the 
same workflow used in the CDKN2A analysis. Whole 
genome expression profiling displayed 3570 transcripts 
differentially expressed in RHC variant (A1 and A2) vs. 
wild-type MC1R skin cells (B1 and B2). Specifically, 
54% of transcripts (1954/3570) were up-regulated 
while 46% (1616/3570) were down-regulated. By class 
comparison, 159 genes showed highly statistically 
significant differences (p < 0.0000001) (listed in Table 
S2). RHC skin cells showed a down-regulation of a 
subset of genes categorized as melanocyte differentiation 
and pigmentation genes. The transcription of most of 
these genes is regulated directly via the MC1R signaling 
pathway, or indirectly through keratinocyte differentiation 
genes (TYRP1, MLANA, TYR, CRNN, PADI1, GDF15, 
MLPH, KIT, INHBB, DAB2, KLK6, FOXC1, and NDRG4). 
Furthermore, RHC variant skin cells exhibited up-
regulation of DNA damage and/or DNA repair response 
genes (BUB1, CHEK1, POLQ, RAD51AP1, RAD54B, 
RAD51C, BLM, UBE2T, GINS2, EXO1, FAM33A, PTTG2, 
PTTG1, RAD54L, DTL), cell cycle and proliferation 
genes (CDKN3, CDC25, CDK1, CCNA2, CDC20, 
CCNB2, CCNB1, CKS, CDCA3, PLK1, PRIM, CDCA8, 
GMNN, CDC6, VRK1, CKS1B, RFC4, CDC45, CENPN, 
HAUS8, PSRC, MCM6, MELK, AURKA, NCAPG) and 
microtubule-based motors kinesin superfamily genes 
(KIF11, KIF15, KIF2C, KIF4A,KIF23). 
The functional enrichment analysis showed a 
considerably higher number of altered pathways in non-
functional MC1R cells than in CDKN2A mutant cells. The 
RHC skin cells displayed over-expression of genes playing 
Figure 2: Set of immunomodulation and interferon response deregulated in mutant CDKN2A co-cultures. The logarithm 
of the Fold change (LogFC) for the set of genes is indicated for wild-type MC1R co-cultures (wt_MC1R; green) and for Red Hair Colour 
MC1R variants co-cultures (RHC_MC1R; yellow).
Figure 3: Deregulated pathways in RHC MC1R melanocyte-keratinocyte co-culture system. In blue are the number of total 
genes annotated within the pathway, in red are the number of deregulated genes in the RHC MC1R co-cultures. The KEGG term is indicated 
for each pathway (axis X). * Pathways related to neurodegenerative diseases.
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a role in major DNA repair and cell homeostasis pathways 
such as DNA replication, cell cycle and also oxidative 
phosphorylation which leads to production of reactive 
oxygen species (Figure 3 and Table 2). The lysosome and 
endocytosis pathways, which are intrinsically related to 
melanosome transfer from melanocytes to keratinocytes, 
were over-represented in the set of down-regulated 
transcripts as a direct consequence of low pigment 
production in RHC skin cells. Interestingly, RHC skin 
cells also exhibited an up-regulation of genes involved 
in neurodegenerative disorders such as Parkinson´s 
disease (hsa05012), Huntington´s disease (hsa5016) and 
Alzheimer´s disease (hsa05010). Although most of the 
genes were involved in several of these pathways, some 
of them were restricted to Huntington’s disease (AP2B1, 
CREB3L4, POLR2H and SOD1), to Alzheimer´s disease 
(NAE1, FAS) or to Parkinson’s disease (PARK7).
Besides the lack of functionality caused by p.R151C 
and p.R160W variants, we also analyzed a possible 
effect on MC1R levels, by the relative quantification of 
MC1R expression. We observed a statistically significant 
reduction in MC1R expression in RHC skin cells 
(ddCt=0.06±0.02) compared to wild-type MC1R skin 
cells (ddCt=0.50±0.07; P-value<0.0001). Furthermore, the 
expression of FARP1, SLFN11, GFPT2, COL5A3, TYRP1, 
LEF1, KRT2, ST6GALNAC3, MLANA, MSMB, SILV, A2M, 
and ALOX5 was evaluated by RT-PCR confirming the 
results obtained in the array (data not shown).
We further examined the overlap between genes 
differentially expressed in both mutant CDKN2A (n=1536) 
and in non functional MC1R cells (n=3570). A total of 
485 genes were altered in the same fashion in both 
mutant CDKN2A and non functional MC1R cells and the 
expression of 136 genes was found inversely correlated 
between both groups. Of these 136 genes (listed in 
Table S3), 30 were up-regulated in mutant CDKN2A and 
down-regulated in non functional MC1R cells and 106 
genes were down-regulated in mutant CDKN2A and up-
regulated in non functional MC1R cells (Figure 4). The 
functional analysis of these 136 genes did not reveal over-
representation of any specific pathway.
In silico model evaluation
We hypothesized that if the altered gene signatures 
observed in non-lesional skin from CDKN2A mutation 
or RHC MC1R variant carriers are critical for malignant 
transformation, these patterns will be maintained across 
the carcinogenic process. To support our hypothesis, 
the expression pattern of the most deregulated genes in 
mutant CDKN2A or RHC MC1R variant skin cells was 
compared to their expression observed in two previously 
published skin cancer datasets. The GSE2503 dataset 
contained the whole genome expression of five squamous 
cell carcinomas (SCCs) and six healthy skin samples[35] 
and the GSE12391 dataset included 23 melanomas (CMs) 
at different stages (radial growth phase or vertical growth 
phase) and 18 common nevi[36]. Due to differences 
in the array platforms used among the studies, only the 
expression of genes present in all datasets was evaluated 
(Figure 5). Thus, MC1R expression pattern analyses 
included 76.1% (121/159) of the most deregulated 
Table 2: Deregulated pathways in RHC 
MC1R melanocyte-keratinocyte co-culture 
system.
KEGG Term STATUS Adj.  P-Value
DNA replication 
(hsa03030)
UP 3.83E-14
Cell cycle (hsa04110) UP 7.87E-14
Mismatch repair (hsa 
03430)
UP 1.56E-06
Nucleotide excision 
repair (hsa03420)
UP 7.01E-06
Oxidative 
phosphorylation 
(hsa00190)
UP 6.91E-05
Homologous 
recombination 
(hsa03440)
UP 6.98E-04
Base excision repair 
(hsa03410)
UP 1.07E-03
Purine metabolism 
(hsa00230)
UP 1.80E-02
Pyruvate metabolism 
(hsa00620)
UP 3.47E-02
Valine. leucine and 
isoleucine degradation 
(hsa00280)
UP 8.13E-03
One carbon pool by 
folate (hsa00670)
UP 2.69E-03
Spliceosome (hsa03040) UP 1.80E-02
Parkinson's disease 
(hsa05012)
UP 3.10E-05
Hugtington's disease 
(hsa05016)
UP 5.25E-04
Alzheimer's disease (hsa 
05010)
UP 3.03E-03
Endocytosis (hsa04144) DOWN 3.83E-02
Lysosome (hsa04142) DOWN 4.70E-03
The KEGG term is indicated for each pathway (X-axis). Status: UP: 
pathway overrepresented in the group of up-regulated transcripts in 
RHC MC1R; DOWN: pathway over-represented in the group of down-
regulated transcripts in RHC MC1R.
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genes. Primary co-cultures with the non-functional 
MC1R gene showed a statistically significant expression 
pattern (p-value <0.005) similar to those detected in 
SCCs (Pearson correlation=0.44) and CMs (Pearson 
correlation=0.25) (Figure 5a). 
Because of platform disparities, the mutant 
CDKN2A expression pattern was evaluated analyzing 
53.7% of the most deregulated transcripts (58/108). 
The expression pattern correlated to those observed in 
SCCs (Pearson correlation=0.35) and CMs (Pearson 
correlation=0.28) showing a statistical tendency among 
datasets (p-value <0.06), in which immunomodulation 
and interferon response genes were also up-regulated 
(SP110, BTN3A2, IL15, IFIT2, IFI44, IFIT1, IFI44L and 
Figure 4: Genes inversely expressed in mutant CDKN2A and RHC MC1R. 136 genes were found inversely expressed between 
mutant CDKN2A and RHC MC1R genes (listed in Table S3). A: RHC MC1R vs wt MC1R (both mutant CDKN2A); B: mutant CDKN2A vs 
wt CDKN2A (both RHC MC1R); C: mutant CDKN2A vs wt CDKN2A (both wt MC1R); D: RHC MC1R vs wt MC1R (both wt CDKN2A).
Figure 5: In-silico model evaluation. Comparison of the expression patterns detected in our study to those observed in Squamous cell 
Carcinomas (SSC; GSE2503 dataset) and Melanomas (MM; GSE12391 dataset).
Fig. 5A: Heatmap MC1R expression pattern showed a positive correlation among datasets (p-value <0.005).
Fig. 5B: Heatmap CDKN2A expression pattern showed a positive correlation among datasets (p-value <0.06). 
Fig. 5C: Subset of genes with an inverse expression pattern between mutant CDKN2A skin cells and SSC and MM. INV: inversely correlated 
pattern.
P=0.027INV
P=0.009
Fig. 5a Fig. 5b Fig. 5c
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CLEC2B; Figure 5b). A correlated expression pattern 
was found within a subset of genes between CMs and 
mutant CDKN2A skin cells (Pearson Correlation=0.66, 
P-value = 0.009; Figure 5c). Remarkably, this subset 
of genes presented an expression pattern that inversely 
correlated between SCCs and CMs (Pearson correlation= 
-0.88, p-value<0.001) and also between SCCs and 
mutant CDKN2A skin cells (Pearson correlation= -0.58, 
p-value=0.027). Specifically, the expression pattern of 
TBX1, CLDN17, RFX2, COL5A3, IFIT2, CEACAM1, 
WDR78, LXN, SLC39A8, ZNF83, RPS27L, LSM3, CTSK, 
and PMP22 was exclusively correlated to MM and mutant 
CDKN2A MM prone skin cells, and inversely with NMSC. 
DISCUSSION
The aim of the study was to determine the 
constitutional effect of germline CDKN2A mutations or 
MC1R variants in skin cancer, in order to identify early 
critical molecular targets implicated in the disease. To 
do so we analyzed co-cultured melanocyte-keratinocyte 
systems derived from two siblings belonging to two 
melanoma prone families with a founder CDKN2A 
mutation and/or carrying non-functional MC1R alleles to 
compare global gene expression profiles.
To date, CDKN2A is the major gene responsible 
for increased melanoma susceptibility in high-risk 
pedigrees. Germline high-penetrance mutations are 
found in 10% of melanoma prone families and somatic 
CDKN2A alterations are also recurrent events in primary 
melanomas[37] and melanoma cell lines[38]. Alterations 
in gene expression in as yet phenotypically normal cells 
but bearing single-hit mutations in tumor suppressor genes 
appear to be the earliest molecular change during cancer 
development[39].  
Altered baseline expression signatures associated 
with CDKN2A mutations in cultured normal skin 
fibroblasts from familial melanoma patients have 
already been reported [40]. However, the transcriptome 
deregulation within keratinocytes and melanocytes where 
cutaneous carcinomas and melanomas arise have not 
been previously assessed. We found that transcriptome 
signatures were altered by single hit CDKN2A mutations 
in co-cultured melanocyte-keratinocyte systems. CDKN2A 
mutant cells exhibit mainly baseline differences in genes 
related to cell components, metabolism and immune 
response. Melanoma cells are addicted to oncogene-
driven energy production which can be mediated by 
somatic BRAF mutations [41], our findings indicate that 
non transformed skin cells already have a deregulated 
metabolic profiling which may be necessary for the skin 
cancer initiation.
Previous studies suggest that genetic variation of 
some cytokines or their receptors influence melanoma 
susceptibility [42, 43] and even modify the risk in 
melanoma-prone families with CDKN2A mutations 
[44]. Consistent with this hypothesis, our data reflects 
the important role of innate immunity and immune 
response pathways which may be deregulated in 
early steps of melanoma development. Skin cells also 
exhibited deregulation of epidermal differentiation and 
melanogenesis genes. Thus, we found down-regulation 
of the TYRP1 gene, a melanocyte differentiation marker 
and over expression of MFI2 gene, a cell-surface 
glycoprotein playing a role in melanoma cell proliferation 
and tumorigenesis [45] and EEA1 gene, a marker of 
early endosomes [46]. Interestingly, EEA1 interacts with 
MFI2 regulating endosome fusion and trafficking [47]. 
Early endosomes are direct precursors of melanosomes, 
which are the specialized organelles for the biosynthesis 
and storage of melanins[46]. These findings may indicate 
that constitutive disorganized melanosomal structures 
and changes in pigment production may favor malignant 
transformation which in turn, could be related to 
autoimmune response deregulation [48, 49]. 
Via functional analyses, we observed a down-
regulation of the Notch signaling pathway in CDKN2A 
mutant cells. This pathway is essential in epidermal-
melanocyte interactions [50, 51] and recent evidence 
suggests Notch pathway as a link between the control 
of epidermal differentiation and proliferation and skin 
homeostasis [52, 53]. Notch signaling has a dual action (as 
oncogene or as tumor suppressor) in skin cancer. While, 
up-regulation of the Notch pathway is observed in CMs or 
in SCCs at sun-protected sites, it is down-regulated in UV-
related solar keratoses SCCs or in common melanocytic 
nevi (reviewed in Panelos and Massi, 2009 [54]). A 
high melanocytic nevi count is the strongest known risk 
factor for melanoma[55] and a potent predictor of mutant 
CDKN2A gene carrier status[56]. Thus, the baseline down-
regulation of the Notch signaling pathway in CDKN2A 
mutation carriers may proffer a melanocyte proliferation 
advantage, which can trigger common nevi development 
in human skin.
The pigmentation related gene MC1R acts as a 
moderate melanoma risk gene and variants in this gene 
are modifying factors for melanoma risk in CDKN2A 
mutation carriers [21-23]. Furthermore, MC1R variants 
have also been clearly associated with elevated NMSC 
susceptibility [19, 20]. We observed that the number of 
genes differentially expressed in non-functional MC1R 
was considerably higher than in mutant CDKN2A. Both 
p.R151C and p.R160W alleles halted MC1R activity and 
also induced an altered cell surface molecule expression 
due to impaired export traffic [57] that could lead to a 
reduction in MC1R gene expression levels as observed in 
our study. We found that RHC MC1R skins cells differ 
from wild-type in the deregulation of genes involved in 
key physiological processes such as differentiation, cell 
adhesion and cell cycle progression which may be directly 
related to the etiology of skin cancer. We found that in 
non-functional MC1R cells, pathways associated with 
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increased DNA damage without UV radiation exposure 
were up-regulated, indicating that RHC variants contribute 
to cancer risk in humans increasing the DNA damage 
mediated by intrinsic UV-independent mechanisms as 
recently observed in mice models [58]. Notably, RHC 
MC1R skin cells also showed up-regulated pathways 
related to neurodegenerative diseases. The MC1R gene is 
expressed in cells of the nervous system and its activation 
decreases oxidative stress and has anti-inflammatory 
and immunomodulatory effects [59]. Co-occurrence 
of Parkinson’s disease (PD) and CMs [60, 61] has been 
reported in epidemiological studies. The diagnosis of CM 
is associated with an approximate 50% increased risk 
of subsequent PD[61] development whereas individuals 
with PD have a two-fold increase in risk of subsequent 
CM[62] development. Previous data suggests that this 
relation is associated with pigment-related genes[63] 
rather than Parkinson’s-related genes[64, 65]. Our study 
further supports that MC1R is involved in the cross-
link between both diseases. Thus, MC1R variants may 
increase the oxidative damage in brain cells and deregulate 
inflammatory processes which consequently, increase the 
susceptibility to neurodegenerative disorders. 
Previous studies showed that many of the alterations 
associated with transcriptome and proteome signatures 
of as yet phenotypically normal cells bearing inherited 
alterations are also present in the corresponding form 
of cancer [39]. Thus, in our study, expression patterns 
detected in MM prone cells from non-lesional areas of the 
skin were compared with those observed in skin cancer 
tumors (SCCs and CMs) [35, 36]. Although differences in 
the experimental designs among studies (normal skin cells 
vs tumoral tissue or cultured cells vs fresh-frozen tissue) 
may interfere in the analysis, the expression patterns 
detected in our study correlate to those observed in skin 
tumors. Interestingly, the MC1R expression pattern was 
more similar among studies than the CDKN2A pattern 
(p-value<0.005 and p-value<0.06, respectively). These 
differences are caused in part by a subset of genes showing 
a converse pattern which allows us to distinguish between 
SSCs versus CMs and mutant CDKN2A skin cells (MM 
prone cells). Accordingly, previous studies have detected 
the inverse expression of two genes from this subset 
(CEACAM1 and CTSK) between SSCs and MMs [66, 
67]. Such differences may underlie the epidemiological 
differences observed between MC1R and CDKN2A and 
skin cancer susceptibility since MC1R polymorphisms 
are involved in both CMM and NMSC susceptibility 
while CDKN2A mutations are closely related to CM 
susceptibility rather than SCC susceptibility.
In conclusion, we have identified baseline 
expression signatures in skin cells carrying germline 
CDKN2A mutations and RHC MC1R variants which are 
maintained in skin tumors (melanoma and squamous cell 
carcinomas). The study identified a large catalogue of 
genes in CDKN2A mutant skin cells that are closely related 
to skin cancer, highlighting the role of genes involved in 
immune response, in melanosome biogenesis and the 
Notch signaling pathway Also, our data indicates that 
non functional MC1R variants promote DNA damage by 
intrinsic UV-independent mechanisms in human skin cells. 
Furthermore, our study revealed a role for MC1R in the 
susceptibility to neurodegenerative diseases which may 
be related to its role in oxidative stress and inflammatory 
processes. 
METHODS
Study Design
To detect the effect of CDKN2A and MC1R genes, 
two melanoma families (A and B) were selected (Table I). 
The most frequent mutation, p.G101W, resulting from a 
common ancestor in Mediterranean pedigrees, was chosen 
in relation to the CDKN2A status. Regarding MC1R status, 
the presence of two red hair variants in each individual 
(RHC: p.R151C and p.R160W) was analyzed. To reduce 
the effect of intra-individual variability, two siblings from 
each family were selected, resulting in four different 
extreme genotypic conditions: a carrier of variants in both 
genes (sample A1), an individual without variants in any 
gene (sample B2) and two carriers of variants in one of 
these genes (samples A2 and B1), respectively. 
The study was approved by the IRB and signed 
informed consents were obtained from all individuals. 
Primary keratinocyte and melanocyte co-culture
Skin biopsies from non-lesional areas were taken 
and human keratinocytes and melanocytes were obtained 
by mechanical fragmentation and enzymatic digestion 
[68]. Briefly, skin biopsy fragments were digested with 
collagenase type I solution (2mg/ml) (Sigma–Aldrich, 
Gillingham, UK) for 90 minutes. The collagenase solution 
was then completely eliminated and the remaining skin 
biopsy was introduced into a mixture of 0.05% trypsin 
/0.02% EDTA (T/E) (Sigma). Every 30 min, T/E was 
changed for a fresh T/E mixture. Collected T/E was 
inactivated with serum containing culture medium and 
was centrifuged at 1400 rpm for 10 minutes. Primary 
keratinocytes and melanocytes obtained by this method 
were cultured on a feeder layer of lethally irradiated 
(X-ray; 50 Gy) 3T3-J2 cells (a gift from Dr J. Garlick, 
SUNY), as previously described [69, 70]. The seeding 
media was a 3:1 mixture of Dulbecco’s Modified Eagle 
Medium (DMEM) (GIBCO-BRL, Barcelona, Spain) 
and HAM’S F12 (GIBCO-BRL) containing 10% FCS, 
0.1 nM choleric toxin, 2 nM T3, 5 µg/mL insulin, 
and 0.4 µg/mL hydrocortisone. Cells were cultured at 
37ºC in a humid atmosphere containing 5% CO2. The 
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culture medium was changed every two days. This co-
culture system has been extensively proven to preserve 
stemness of keratinocytes[69-71] as well as to maintain 
the physiological melanocyte:keratinocyte ratio (1:40)[72, 
73]. Moreover, by using the skin cells from this type of 
co-culture, the donor’s phenotypic pigmentation and UV-
response features are preserved in vivo on a humanized 
skin mouse model[74].
RNA extraction
Total RNA isolation from primary cultures on 
passage 3-4 was performed using the Trizol extraction 
method (Invitrogen Life Technologies, Carlsbad, 
CA) followed by purification in commercial columns 
(Qiagen, Valencia, CA). Total isolated RNA was further 
purified using an RNeasy kit (Qiagen, Valencia, CA). 
RNA concentration was determined using a NanoDrop 
Spectrophotometer (Thermo Scientific) and integrity 
of the RNA was verified by Bioanalyzer 2100 (Agilent, 
USA). The RNA integrity number was in all cases higher 
than 8.
Expression array
Analysis of global expression was performed using 
the Whole Human Genome (4x44k) Oligo Microarray kit 
(G4112F, Agilent, US). The microarray contains probes 
from over 41,000 unique human genes and transcripts, 
all with public OMIM annotations (RefSeq, Goldenpath, 
Ensembl, Unigene Human Genome and GenBank 
databases). Overall, 50 ng of RNA were labeled using 
Low input Quickamp Labeling kit (Agilent, US). In all 
samples 10 commercial controls probes were added 
in order to standardize the results (RNA Spike-in kit, 
one color, Agilent, US). The arrays were scanned using 
the DNA Microarray Scanner G2565CA (Agilent, US). 
Finally, Feature Extraction Software (FES, Agilent, USA) 
was used both to perform the quality control process and 
to extract the information. Three replicates from each 
primary culture were analyzed.
Quantitative real-time reverse transcriptase 
polymerase chain reaction (qRT-PCR) of selected 
genes
To confirm the microarray results, the expression 
of 13 genes (FARP1, SLFN11, GFPT2, COL5A3, TYRP1, 
LEF1, KRT2, ST6GALNAC3, MLANA, MSMB, SILV, 
A2M, and ALOX5) was validated by RT-PCR. Also, MC1R 
expression was evaluated. The ACTB gene was used for 
normalization. RNA derived from donors’ healthy skin 
was used as a calibrator in each reaction. A total of 200 ng 
of RNA was retrotranscribed to cDNA using Taqman PCR 
Core Reagent kit (Roche Applied Science, Penzbergf, 
Germany). Real-time PCR was performed using Taqman 
Universal PCR master Mix (Roche Applied Science, 
Penzbergf, Germany). Reaction was performed in an ABI 
Step One plus RT-PCR sequence detection instrument 
(Applied Biosystems, CA, US). Primer design and gene-
specific probe selection were carried out by the Universal 
Probe Library software (UPL, Roche, Mannheim, 
Germany).
Data was evaluated using the relative quantification 
method of  ddCt[75]. Expression values were evaluated by 
T-test for equality means using the SPSS 17.0. P-values 
less than or equal to 0.05 were considered statistically 
significant.
Microarray data and statistical analyses
The Agilent Processed Signal was standardized 
across arrays using quantile normalization[76]. 
Differential gene expression analysis was carried out using 
the limma package from Bioconductor. Multiple testing 
adjustments of p-values were performed according to 
Benjamini and Hochberg methodology[77].
Gene set analysis was carried out for the Kyoto 
Encyclopedia of Genes and Genomes pathways (KEGG) 
using FatiScan[78] in Babelomics[79]. This tool detects 
significantly up- or down-regulated blocks of functionally 
related genes in lists of genes ordered by different criteria 
such as differential expression, KEGG pathways and 
others. The core of the method is based on an algorithm to 
test whether a set of genes, labeled with terms (biological 
information), contain significant enrichments of one 
or several of these terms with respect to another set of 
reference genes. FatiScan uses a Fisher’s exact test for 
2×2 contingency tables for comparing two groups of genes 
and extracting a list of KEGG terms whose distribution 
among the groups is significantly different. Given that 
many KEGG terms are simultaneously tested, the results 
of the test are corrected for multiple testing to obtain an 
adjusted p-value. FatiScan returns adjusted p-values based 
on the False Discovery Rate (FDR) method[77]. KEGG 
Pathways for the genes in the microarray where taken 
from the KEGG web. 
In order to gain insight into the co-regulation 
patterns on transcript expression profiles, data from our 
microarray experiments were clustered together with 
expression data obtained from two previous experiments 
focused on NMSC (GSE2503 dataset[35]) and MM 
(GSE12391 dataset[36]). Raw data were obtained from 
the Gene Expression Omnibus. For each dataset we 
analyzed the differential expression and determined the 
fold-changes. We selected two subsets: genes differentially 
expressed in our study for the MC1R comparison (RHC 
alleles vs. wild-type MC1R) and a second group of genes 
differentially expressed in our study for the CDKN2A 
comparison (p.G101W vs. wild-type CDKN2A). In each 
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scenario, fold-changes were normalized using the quantile 
method[76] to compare differential expression results in 
all experiments. We performed a hierarchical clustering 
analysis of differentially expressed transcripts and the 
graphical representation showed the relationship between 
experiments. The correlation analysis quantified the linear 
relationship between the different studies m
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